VENTANA MMR RxDx Panel

FDA Premarket Approval P210001

Pre-market Approval Supplement Details

Approval for the ventana mmr rxdx panel as a cdx for identifying patients with solid tumors with dmmr status who may benefit from treatment with jemperli.

DeviceVENTANA MMR RxDx Panel
Generic NameImmunohistochemistry Test, Dna Mismatch Repair (mmr) Protein Assay
ApplicantVentana Medical Systems Inc (Roche Tissue Diagnostics)
Date Received2021-01-22
Decision Date2021-08-17
PMAP210001
SupplementS
Product CodeQNH 
Advisory CommitteePathology
Expedited ReviewNo
Combination Product No
Applicant Address Ventana Medical Systems Inc (Roche Tissue Diagnostics) 1910 E. Innovation Park Drive tucson, AZ 85755

Supplemental Filings

Supplement NumberDateSupplement Type
P210001Original Filing
S007 2022-10-14 30-day Notice
S006 2022-07-12 30-day Notice
S005 2022-04-28 Normal 180 Day Track No User Fee
S004
S003
S002
S001 2021-08-18 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.